Pfizer
Maha Habib is an accomplished professional with extensive experience in clinical trial management and project leadership. Currently serving as the Director and Clinical Study Team Lead at Pfizer since June 2022, Maha previously held positions at Bristol-Myers Squibb as a Clinical Protocol Manager and Study Manager from June 2015 to July 2022. Other notable roles include Senior Specialist in Study Management at AstraZeneca and Senior Study Management Associate at Allergan, Inc. Early career experience includes Clinical Project Manager at Frontage Laboratories, Inc. and support roles at Johnson & Johnson. Maha holds a BA in Biology from Rutgers University, earned between 1998 and 2003.
This person is not in the org chart
This person is not in any teams
Pfizer
614 followers
Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.